We built the report we could not buy

The tools to understand inherited longevity biology and current biological state now exist separately and affordably. Whole-genome sequencing at clinical depth has fallen to consumer prices. Methylation clocks are repeatable. Clinical biomarkers are routine.

What does not exist, outside programmes costing many thousands, is the work of reading those layers against each other — deciding which findings deserve attention, which reinforce one another, which contradict, and which should simply be left alone.

That interpretation work is what Aevum is. We are not selling another test. We are building a record of a person's biology that becomes more useful every year, held to standards that a clinician can audit and a sceptic can check.

Our operating principle is simple: never claim more than the evidence supports, and never let caution flatten a finding that genuinely matters.